我叫 Georgios Kokolakis，至今已有约 18 年从业经历，目前在柏林夏里特医学院皮肤科工作。现在我是那里的研究员，日常既要接诊患者，也要推进自己的研究项目，专业方向是炎症性皮肤病学，重点研究银屑病和化脓性汗腺炎（HS）。
我觉得这次会议非常有意思，不仅因为能接触到最新研究数据，更因为能和同行交流、拓展人脉 —— 在会上能结识很多同行。而且巴黎是个很棒的城市，特别适合举办这类大型会议，这次会议就像皮肤科领域的盛会，既有学术交流，也有社交互动。我在这次大会上展示了多张壁报，下面想介绍其中两个我认为最有意思的研究。
第一张壁报的研究是与德国 Almirall Hermal GmbH 公司合作完成的（该公司为研究赞助商），核心是探究两类患者对治疗的期望：65 岁以下的年轻患者，以及 65 岁以上的老年患者。以往我们通常假设老年患者的治疗需求少于年轻患者，但这项研究发现，两组患者对治疗的期望和需求完全相同，主要围绕治疗有效性和自身生活质量提升。因此，所有患者都应得到同等优质的治疗，无关年龄 —— 这是第一张壁报的核心内容。
其实我认为 EADV 大会最有价值的一点是，它是一个高度注重临床应用的大会。大会既涵盖基础研究（如免疫学、转录组学新数据、罕见病等领域），也包含临床研究 —— 我们既能接触基础研究成果，也能看到这些知识在临床实践中的应用。这种 “基础 + 临床” 的结合，正是我们为患者开发新型疗法和药物的关键。值得一提的是，EADV 大会不局限于单一领域，而是将临床实践与实验室研究很好地融合在了一起。
My name is Georgios Kokolakis, and I've been working since about 18 years, now at the clinic of dermatology in the Charite University Hospital in Berlin. I work now as a fellow researcher there and I do my patients my projects as well, so I specialize on inflammatory dermatology, with a focus on psoriasis and HS.
I found this meeting really interesting not only because of the new data but because of the networking of the colleagues that you can meet there, and I think Paris is an exciting city to do such a big meetings, I think it's like a big party for the dermatology not only for the scientific part but also for the social part. I had several posters in this Congress, maybe I can refer to two of them, which I found most interesting.
The first was actually a poster that we did with a company in Germany Almirall Hermal GmbH—it's the sponsor—and we focused on the wishes of the patients: the young patients (younger than 65 years old) and the therapy and treatment wishes of older patients (older than 65 years old). We always assume that older patients have fewer needs than young patients, but what we found in this study was that both groups have the same wishes and needs from therapy, related to the effectiveness of the therapy and their well-being. So all patients should be treated equally well, regardless of age—that’s the key point of the first poster.
Actually, what I find interesting about EADV is that it’s a very clinically oriented Congress. It includes basic research (like immunology, new transcriptomics data, and rare diseases) as well as clinical research—we get to see both basic knowledge and its application in clinical practice. This combination is how we develop new medications and drugs for patients. What’s great is that EADV covers both sides, not just clinical practice or laboratory research, but a mix of both.
